SLC7A11 and liver cancer: While there are currently no FDA-approved medications that selectively target SLC7A11/xCT, there is growing interest in SLC7A11 inhibitors in the cancer field, as SLC7A11 overexpression promotes tumor growth partially by suppressing ferroptosis, which might also be relevant to alcohol-related liver cancers [74, 75].